Among patients with coronary artery disease, the likelihood of cessation from smoking increases with the severity of symptoms and signs of disease. [9] [10] [11] Patients with unstable angina are more likely to quit smoking than those with stable angina. 12 The rate of smoking cessation in patients with angiographically confirmed coronary artery disease varies from 35% to 75%. 9-11 13 Providing smoking cessation advice to patients who have been hospitalised with a coronary condition results in a 50% long term (more than one year) abstinence rate. 7 14 Abstinence at one year is achieved in two thirds of smokers after percutaneous coronary revascularisation and advice from physicians using a comprehensive risk factor intervention and regular follow up. 15 When patients with IHD quit smoking they have a 50% reduction in risk of reinfarction, sudden cardiac death, and total mortality after the initial infarction. [16] [17] [18] However, despite the proved benefits of smoking cessation after percutaneous coronary revascularisation, many patients continue to smoke after the procedure. 12 19 Additionally, smokers at one year following coronary bypass surgery had more than twice the risk for myocardial infarction and reoperations than never and ex-smokers; the risk was also higher at five years.
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Clinical approaches
Two decades of clinical trials conducted in general practice have demonstrated that the general practitioner has a major role to play in tobacco control, and there is a strong, positive dose-response relation between both intensity and duration of treatment and successful cessation. 21 When a general practitioner gives very brief advice to quit and a pamphlet on smoking cessation strategies, this yields 5-10% abstinence at one year. [22] [23] [24] With longer and more intensive intervention including strategies for quitting, nicotine replacement treatment, and follow up visits, cessation rates of 15-36% at one year are achieved. [25] [26] [27] [28] These cessation rates are much greater than the 4% maintained in the general population. 21 There are several smoking cessation guidelines for medical practitioners-for example, the Agency for Health Care Policy and Research (AHCPR) guideline is based on evidence from more than 300 published studies. 21 The "Smokescreen program" described below is a programme used by general practitioners in Australia and New Zealand, and has been promoted to physicians through the Royal Australasian College of Physicians. 29 In our studies in general practice with more involved interventions conducted among healthy smokers with no IHD and with varying degrees of motivation to quit, there were modest cessation rates (19% 26 36% 25 ).
SMOKESCREEN PROGRAM
Every patient should be asked if they smoke and should be advised about their smoking at each visit. Many doctors' past failures with patients have resulted from trying to persuade smokers who are not yet ready to quit. The "Stages of change model" 30 recognises that at any one time there are 20% of smokers in the general population who are ready to quit, 40% who are unsure about whether to quit, and 40% who are not ready to quit. 31 An assessment needs to be made about patients' readiness to quit so that the appropriate intervention can be delivered. The first step when intervening with smokers is to ask whether they are ready to stop smoking. Just because the patient with IHD has been advised to quit, does not mean that he or she is ready to stop and will be successful. The next step is to allocate the patient to one of the three readiness groups. This is accomplished by asking: "How do you feel about your smoking?" 32 This open ended question raises the issue of smoking in a non-confrontational way and leads to dialogue in which readiness to quit can be determined. If it is still unclear, then asking: "Are you ready to quit now?" provides a more definitive answer.
When the doctor and patient have ascertained stage of readiness, the next step is to provide the appropriate brief smoking intervention. Patients who are not ready to quit, want to smoke and they do not acknowledge the negative aspects of smoking as more important. Personalising smoking as a major risk of heart disease and emphasising the benefits of quitting encourages patients not ready to quit to consider the pros and cons of smoking. The advice should be no more than a couple of minutes as these smokers are not ready to change at this time.
Patients who are unsure or ambivalent about smoking, have concerns about the eVect of smoking on health, but are also aware of the disadvantages to quitting. The aim is to motivate smokers who are unsure to change and become ready to quit. A technique called brief motivational interviewing 33 is useful in enabling the unsure patient to weigh the pros and cons of smoking so that a decision can be made to try and quit. 
A key principle of motivational interviewing is that the patient takes responsibility for the smoking problem. Patients are more likely to make a decision to stop smoking if they have reached it on their own. The time spent with unsure patients is five minutes and self help materials available from health organisations can be provided.
Common barriers to quitting include concern about withdrawal, high dependence on nicotine, low motivation to quit, excessive alcohol use, and a family, work, and social environment with a predominance of smokers. If the physician assists in the change process so that the patient moves from being unsure to attempting to quit, then the consultation is regarded as successful. The next stage is to advise about quitting.
Physicians think that all patients are ready to quit if they advise them to stop smoking. Clearly this is not the case, although there may be compelling cardiac and other reasons why the patient should stop. Interventions in the 1980s were designed mainly for the small group of smokers ready to quit. These smokers have made a serious commitment to try and stop smoking and appreciate that the disadvantages of smoking outweigh the benefits.
Patients who are ready to stop require an active intervention consisting of cognitive and behavioural strategies as well as nicotine replacement to help them overcome withdrawal symptoms. As the cardiologist has limited time to advise on smoking, there are three main issues to discuss. First, it is important for the patient to set a date to stop smoking. Second, give the smoker a booklet that outlines many of the strategies for successful quitting including activities that distract, avoid, and delay smoking. Finally, available time should be spent explaining the eVective use of nicotine replacement.
Nicotine replacement
Two thirds of patients experience some withdrawal symptoms such as severe craving to smoke, insomnia, dizziness, loss of concentration, nervousness, tiredness, headaches, lightheadedness, and irritability. Withdrawal symptoms are signs of recovery, and the worst of these symptoms subsides in the first week of stopping and most symptoms have disappeared in 10-12 days. Patients who smoke more than 15 cigarettes per day are likely to be nicotine dependent and concerned about suVering withdrawal symptoms. Nicotine gum and patches are valuable aids for quitting. Nicotine gum and transdermal nicotine patches are available over the counter in many countries. It is advisable to caution patients not to smoke while using these aids as this is predictive of failure to quit smoking. 34 Although both gum and patches are eYcacious, in general, the patch is preferable for routine clinical use. Use of the active patch doubles success rates compared to placebo. 35 Transdermal nicotine has been shown to be safe for patients with stable IHD, 36 37 and does not aVect angina frequency, overall cardiac symptom status, arrhythmias, or episodes of ischaemic ST segment depression. 36 A nicotine nasal spray is available on prescription (in the UK and USA), and a nicotine inhaler will be available soon. Providing advice on quitting for "ready" smokers will add another 5-10 minutes to the consultation.
The smoking status of all cardiac patients should be assessed and the appropriate brief intervention oVered to smokers according to their readiness to quit. The patient who has a clinical illness is likely to be motivated to change, and the consultation is a powerful setting to advise about quitting. Reducing the proportion of the population that smokes should be a multipronged campaign including the cardiologist and general practitioner who proactively encourage their patients to quit, antismoking advertising, increasing the price and taxes on cigarettes, and primary prevention initiatives among children and adolescents. 
STAMPS IN CARDIOLOGY
Aspirin
In the 17th and 18th centuries cinchona bark from South America was the preferred treatment for pain and fevers but in 1763 the Reverend Edward Stone of Chipping Norton found that bark of the willow tree, Salix alba, was an eVective substitute. By 1829 the active compound had been isolated and named "salicin". In 1838 salicylic acid was prepared from salicin and it was also prepared from the meadowsweet, Spiraea ulmaria. Salicylic acid was a good analgesic and antipyretic; by 1860 it had been synthesised and later 24 000 kilograms a year were being produced. However, it irritated the mouth and stomach and these side eVects led to the search for a better compound. This was achieved at the Bayer laboratories in Leverkusen by the chemist Dr Felix HoVmann (1868−1946) on 10 August 1897 when he produced a pure and stable form of acetylsalicylic acid. It was a tremendous success and Bayer's trade name, "Aspirin" became world famous. The name comes from "a" for acetyl, "spir" from Spiraea, and "in" as a common ending for a drug. The only stamp issued on this theme comes from Uruguay in 1997 to mark the centenary of the synthesis of acetylsalicylic acid. A booklet of two stamps was issued and the front cover depicts Dr Felix HoVmann, a branch of the willow tree, and his signature taken from his laboratory record of 10 August 1897. Bayer supplied aspirin to dispensing chemists in 250 g glass bottles (circa 1899), which are pictured inside the booklet, and the back cover bears the Bayer logo.
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